Crossject Logo

Crossject

ALCJ | PA

Overview

Corporate Details

ISIN(s):
FR0004178614 (+6 more)
LEI:
969500W1VTFNL2D85A65
Country:
France
Address:
6 Rue Pauline Kergomard, 21000 dijon
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Crossject is a specialty pharmaceutical company that develops drug-device combinations for emergency medical situations. Its core product is ZENEO®, a proprietary and patented needle-free auto-injector platform. This pre-filled, single-use device is designed for the rapid, safe, and easy administration of life-saving medications by patients or untrained caregivers. The technology propels medication through the skin in less than a tenth of a second. Crossject's product pipeline leverages the ZENEO® platform to address critical conditions such as epileptic seizures, adrenal crisis, and allergic shock, aiming to revolutionize drug delivery in emergency medicine.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Crossject. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-04 17:35
Regulatory News Service
CROSSJECT reste mobilisé pendant la coupure estivale
French 387.7 KB
2025-08-04 17:35
Regulatory News Service
CROSSJECT remains engaged during the summer break
English 374.9 KB
2025-07-08 17:30
Capital/Financing Update
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S1 2025
French 116.1 KB
2025-07-01 07:30
Delisting Announcement
CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liqu…
French 105.6 KB
2025-06-24 19:00
Share Issue/Capital Change
CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 mil…
French 213.9 KB
2025-06-24 19:00
Share Issue/Capital Change
CROSSJECT announces a successful capital increase of €5.7 million following ful…
English 206.2 KB
2025-06-11 07:30
Earnings Release
CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les…
French 108.9 KB
2025-06-11 07:30
Regulatory News Service
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epi…
English 110.5 KB
2025-06-06 17:45
Declaration of Voting Results & Voting Rights Announcements
Crossject : Information relative au nombre total de droits de vote et d'actions…
French 152.9 KB
2025-06-04 20:21
Share Issue/Capital Change
Lancement d’une augmentation de capital avec maintien du droit préférentiel de …
French 292.3 KB
2025-06-04 20:21
Share Issue/Capital Change
Launch of a capital increase with preferential subscription rights for nearly …
English 216.7 KB
2025-06-03 07:30
Investor Presentation
Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat …
French 100.9 KB
2025-06-03 07:30
Earnings Release
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommenda…
English 100.8 KB
2025-05-27 07:30
Regulatory News Service
CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘…
English 111.6 KB
2025-05-27 07:30
Regulatory News Service
CROSSJECT met en place un nouveau module de fabrication pour augmenter la polyv…
French 108.8 KB

Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Crossject via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-24 N/A Other Buy 20,000 N/A
2024-06-14 N/A Other Other 10,979 20,289.19 EUR
2024-06-06 N/A Other Other 1,058,617 1,956,324.22 EUR
2024-06-06 N/A Other Other 16,106 29,763.89 EUR
2024-06-06 N/A Other Other 10,275 18,988.20 EUR
2024-06-06 N/A Other Other 10,074 18,616.75 EUR
2024-06-06 N/A Other Buy 5,536 10,230.53 EUR
2023-03-06 N/A Other Other 22,859 75,434.70 EUR

Peer Companies

Company Country Ticker View
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celon Pharma S.A. Logo
An integrated biopharma company developing drugs for neurology and cancer, from R&D to market.
Poland CLN
Chemical Works of Gedeon Richter Plc Logo
Develops and markets drugs for women's health, CNS, and cardiovascular conditions worldwide.
Hungary RICHT
Chiome Bioscience Inc. Logo Japan 4583
Chordia Therapeutics,Inc Logo Japan 190A
CHUGAI PHARMACEUTICAL CO., LTD. Logo Japan 4519
CHUKYOIYAKUHIN CO.,LTD. Logo Japan 4558
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS